Introduction
The novel coronavirus, Severe Acute Respiratory Syndrome
(SARS)-Coronavirus (CoV)-2 first identified in 2019 in Wuhan region,
China resulted in worldwide COVID-19 pandemic uniting clinicians and
researchers from many countries desperately searching for effective
clinical interventions. The United States of America are one of the
countries with highest incidence of COVID-19 with 1.042.874 cases
diagnoses and 61.123 of total deaths by April 30, 2020 (University,
2020). SARS-CoV-2 belongs to the family of Coronaviridae, positive-sense
single stranded RNA viruses that frequently cause mild respiratory
infections in humans. During the past two decades two endemics with
SARS-CoV in 2003 and Middle East Respiratory Syndrome (MERS)-CoV in 2012
occurred with estimated case-fatalities of 14-15% or even 35% in case
of MERS-CoV. (Gao et al., 2020). COVID-19 disease has wide range of
clinical presentations from asymptomatic cases to severe respiratory
involvement acutely progressing to Acute Respiratory Distress Syndrome
(ARDS) and multi-organ failure. A growing body of literature on COVID-19
reports atypical presentation of ARDS (Gattinoni, Coppola, Cressoni,
Busana, Rossi & Chiumello, 2020), a result of host immune system
overactivation and fatal hypercytokinemia, leading to tissue injury and
multi-organ failure, which may be attributed to an overactivated
complement system (Gao et al., 2020; Lipworth, Chan, Lipworth & RuiWen
Kuo, 2020; Magro et al., 2020).